Goldman Sachs Comments on Gilead Sciences

Goldman Sachs provided color on Gilead Sciences GILD in a research report published today. Goldman Sachs has a Buy rating on Gilead Sciences. In the report, Goldman Sachs states, "GILD licensed the rights to Boehringer Ingelheim's (BI) non-catalytic site integrase inhibitors (NCINIs) for the treatment of HIV, including the lead compound BI-224436 in Phase I. NCINI's have the potential to be a novel class of HIV drugs that target the HIV integrase (responsible for integrating the viral DNA into the host) in a different way than existing integrase inhibitors (Isentress and elvitegravir)." Shares of Gilead Sciences were trading at $39.10 at the time of posting, down 0.13% from Wednesday's market close.